Elemento Decorativo

ANTIBIOTIC LINE

This product line was formulated to satisfy all therapeutic needs of veterinarians. We pride on the quality, safety and effectiveness standards of our products,
as well as on their practical and user-friendly formats.




Medicine Safety,
Animal Safety

Therapeutic efficacy

Foto linea antibiótica

Antimicrobial
Chemotherapeutic

Effectrim®

INDICATIONS

Effectrim® is indicated to treat infections of the respiratory, urinary and digestive tracts, among others.
Acute bacterial respiratory diseases: pneumonia, bronchitis, laryngitis, pleurisy.
Urogenital diseases: nephritis, pyelonephritis, metritis, cystitis, vaginitis.
Digestive diseases: enteritis, diarrhea, peritonitis, intestinal infarction, colitis-x, neonatal foal diarrhea.
Other uses of Effectrim® included the treatment of actinobacillosis, septic arthritis, equine adenitis, omphalitis, and osteomyelitis, among others.
It may be used concomitantly with pyrimethamine for the treatment of equine protozoal myeloencephalitis caused by sarcocystis neurona.

Directions For Use: DOSAGE
A 33 g syringe contains: 12.89 g of sulfadiazine and 2.57 g of trimethoprim. The content of one prefilled syringe is enough to treat a 600 kg horse at the recommended dose rate.
Each graduation on the calibrated syringe delivers sufficient paste to treat 100 kg bodyweight.

Adult horses:
5.5 g of paste per 100 kg of body weight every 12 hours.  

Foals:
5.5 g of paste per 100 kg of body weight every 12 hours. 
Equine protozoal myeloencephalitis:
20 mg/kg orally twice a day, concomitantly with pyrimethamine (1 mg/kg orally once a day.)

DOSING INTERVAL
Every 12 hours.

DURATION OF TREATMENT
15-21 consecutive days of treatment are recommended, consistent with individual response and the onset of adverse effects (refer to package insert for a complete list), in which case treatment should be discontinued.

Content: 33 g prefilled syringe.
Oral paste.

 
  

Ingredients

Sulfadiazine sodium……….………….39,07 g
Trimethoprim………….……….……..……7,81 g
Excipients q. s…………..………..100,00 g

Antimicrobial Antibiotic
Macrolide

Rhodocín®

INDICATIONS

Rhodocín® is a broad spectrum macrolide antibiotic used for the treatment of bacterial infections, particularly those caused by Rhodococcus equi in foals. Its ingredient, azithromycin, may be used alone or concomitantly with rifampicin.
Rhodocín® is indicated to treat respiratory, dermatologic, urogenital, gastrointestinal, and osteoarticular infections caused by bacteria and coccidia susceptible to azithromycin.
Open or drained wound and abscess infections caused by Streptococcus spp. or Staphylococcus spp. may be treated with Rhodocín®.
Rhodocín® proved to be effective against gram-negative bacteria found in gastrointestinal infections caused by Escherichia coli, Haemophilus influenzae, Bordetella spp., Mycoplasma pneumoniae, and Toxoplasma spp.

Directions For Use: DOSAGE
10 mg/kg of body weight.
A 36 g syringe contains 3 g of Azithromycin, half a syringe is enough to treat a 150 kg horse.

Foals:
6 g of paste per 50 kg of body weight every 24 hours. 
Adult horses:
6 g of paste per 50 kg of body weight every 24 hours. 

DOSING INTERVAL
Every 24 hours.

DURATION OF TREATMENT
Administer once daily for 7 consecutive days until clinical signs stabilize. Thereafter, extend dosing intervals to 48 hours until remission.

Content: 36 g prefilled syringe.
Flavored oral gel.

 
  

Ingredients

Azithromycin………………………………8,33 g
Excipients q. s…………..……..100,00 g

Antimicrobial / Antibiotic
Broad Spectrum

Rifamex®

INDICATIONS

Rifamex® is a broad spectrum antibiotic mainly effective against gram-positive bacteria, some gram-negative aerobic bacteria and some facultative anaerobes.
Since most infections are caused by more than one bacterial species, and because of the ability of these microorganisms to rapidly develop resistance, Rifamex® is generally used concomitantly with other antimicrobial agents.
The effectiveness of Rifamex® has been demonstrated in the treatment of infections caused by Staphylococcus spp. and in the eradication of pathogens located in places inaccessible to other antimicrobial drugs, such as the inside of phagocytic cells. It also showed in-vitro activity against Corynebacterium pseudotuberculosis, Lawsonia intracellularis, Rhodococcus equi, species of Staphylococcus, Streptococcus equi, S. equisimilis and S. zooepidemicus.
Rifamex® is used concomitantly with azithromycin for the treatment of pneumonia caused by Rhodococcus (Corynebacterium) equi and equine proliferative enteropathy (Lawsonia intracellularis) in foals.
The results of in-vitro studies and a vast number of registered cases evidence the synergistic effect of the concomitant use of azithromycin and rifampicin against R. equi, favoring the indication of both drugs over the use of azithromycin alone.

Directions For Use: DOSAGE
5 - 10 mg/kg of body weight.
A 36 g syringe contains 6 g of Rifampicin, quarter a syringe is enough to treat a 150 kg horse. 

Foals:
3 g of paste per 50 kg of body weight every 12 hours. 
Adult horses:
3 g of paste per 50 kg of body weight every 12 hours. 

DOSING INTERVAL
Every 12 hours.

DURATION OF TREATMENT
5 to 7 days, according to instructions from the attending veterinarian.
Lawsonia intracellularis: Foals, 21 days. For 1 to 3 months, subject to individual response.

Content: 36 g prefilled syringe.
Oral gel.

 
  

Ingredients

Rifampicin…………………………16,66 g
Excipients q. s……………..100,00 g

Broad-spectrum Cephalosporin
Antibiotic
steroidal anti-inflammatory

Equiceft D®

INDICATIONS

EQUICEFT D® is indicated for the treatment of specific and nonspecific infections caused by germs sensitive to Ceftiofur and also in cases where it is necessary to reduce inflammation and edema.
For the treatment of respiratory tract infections, pneumonia, bone and soft tissues infections, osteomyelitis, septic arthritis, neonatal septicemia, wound infections, Skin infections. Urinary tract infections, placentitis and prostatitis.

DOSAGE:
Adult horses:
2.2 - 4.4 mg/kg of Ceftiofur sodium every 12-24 hours, IM or IV.
0.05 - 0.2 mg/kg of Dexamethasone 21-phosphate every 12-24 hours, IM or IV.

Foals:
2.2 - 5 mg/kg of Ceftiofur sodium every 12-24 hours, IM or IV.
0.05 - 0.2 mg/kg of Dexamethasone 21-phosphate every 12-24 hours, IM or IV.

  • 1 ml of reconstituted Equiceft-D contains 50 mg of Ceftiofur sodium + 4 mg of Dexamethasone 21-phosphate.
  • 20 ml of reconstituted Equiceft-D contains 1000 mg of Ceftiofur sodium + 80 mg of Dexamethasone 21-phosphate.

In cases of septic arthritis or limb infections, administer 1000 mg of Ceftiofur + 80 mg of Dexamethasone dissolved in 20-60 ml of physiologic saline solution every 24 hours for 3-7 days via intravenous regional perfusion administration. Concomitant use with an aminoglycoside antibiotic is recommended (amikacin or gentamicin) and the systemic administration of antibiotics should be considered.

In cases of uterine infections, administer 1000 mg of Ceftiofur + 80 mg of Dexamethasone dissolved in 100-250 ml of warm physiologic saline solution every 24 hours for 3-7 days by intrauterine administration.
For infections caused by gram-positive germs, administer 2.2 mg/kg, IV or IM, every 12-24 hours.
For infections caused by gram-negative germs, E. coli 4.4 mg/kg, IV or IM, every 12 hours.
Doses of Ceftiofur higher than 11 mg/kg/day have been indicated for the treatment of refractory infections.
Dosage and infusion rate may vary according to the instruction of the attending veterinarian.

Dosing interval
Foals: every 12-24 hours.
Adult horses: every 12-24 hours.
Septic arthritis: every 24 hours.
Uterine infections: every 24 hours.
Infusion rate may be slightly modified, according to instructions from the attending professional.

Duration of treatment
5-7 consecutive days of treatment are recommended, consistent with individual response. Treatment should be discontinued if adverse effects are observed.

Content:
Vial 1
5 g of Ceftiofur sodium lyophilized powder, ready for reconstitution.

Vial 2
400 mg of Dexamethasone 21-phosphate plus excipients in 100 total ml of solvent.

 
  

Ingredients

Vial 1
Ceftiofur sodium………….….………………………5,00 g
Vial 2
Dexamethasone 21-phosphate……………0,40 g
Water for injection q. s……….…..100,00 ml

Broad-spectrum tetracycline antibiotic
Local anesthetic

Tetrafen®

INDICATIONS

Tetrafen® is a painless sterile injectable broad spectrum antibiotic indicated for the treatment of infections caused by gram-positive and gram-negative microorganisms, mycoplasmas, protozoa and rickettsiae susceptible to oxytetracycline. Other uses of Tetrafen® include its application in cases of staphylococcal and streptococcal wounds and infections; joint and omphalic infections; genitourinary infections and pre- and postoperative treatments; leptospirosis, metritis, nephritis, pneumonia, omphalophlebitis, pasteurellosis. This product is effective against the following microorganisms: Actinobacillus lignieresii, Actinomyces bovis, Aerobacter aerogenes, Anaplasma marginale, Bacillus anthracis, Bordetella bronchiseptica, Borrelia anserina, Brucella canis, Campylobacter spp., Clostridium chauvoei, Clostridium perfringens types B, C and D, Clostridium septicum, Corynebacterium pseudotuberculosis, Corynebacterium pyogenes, Corynebacterium renale, Erysipelothrix insidiosa, Erysipelothrix rhusiopathiae, Escherichia coli, Fusiformis necrophorus, Haemophilus spp., Klebsiella pneumoniae, Leptospira spp., Listeria spp., Mycoplasma spp., Moraxella bovis, Nanophyetus salmincola, Pasteurella spp., Salmonella spp., Shigella spp., Staphylococcus spp., Staphylococcus aureus, Streptococcus spp., Chlamydiae, Mycoplasmas and Rickettsiae.

Recommendation for Use:
Dosage:

Adult horses:
10 mg / kg of body weight.
0.2 ml / kg of body weight.
1 ml / 5 kg of body weight, IM or SQ.
Do not administer more than 10 ml per injection site.
For intravenous administration, dilution in water for injection or physiological saline is recommended. Doses of up to 2500 mg (50 mL) can be diluted in 250 mL of diluent, and larger doses in 500 mL of diluent.

Dosing interval
Every 24 hours.

Duration of treatment:
5-7 consecutive days of treatment are recommended, consistent with individual response. Treatment should be discontinued if adverse effects are observed.

Content:
100 ml and 250 ml vial.
Sterile injectable solution ready to use.

 
  

Ingredients

Oxytetracycline base…………………………….. 5,00 g
Lidocaine hydrochloride…………………… 1,00 g
Excipients q. s.………………………………100,00 g

Código QR Data Fiscal
Contact
  • info@ivslab.com
  • [54 9] 02342.15568003
  • Ruta Nacional Nº 5, Km 209,200 (B6640) Bragado - Province of Buenos Aires